AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01527240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclosprin A
Description: The dose in this study was 2 mg / kg, administered within 15 min after beginning of thrombolysis. The treatment of the study consists of a single bolus injection. This dose was chosen according to the results of tolerance in myocardial infarction and unknown pharmacodynamic and safety data
Study NCT01527240 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Injectable Saline Solution.
Description: Saline Solution is administered once 15 min after thrombolysis.
Study NCT01865318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Administered subcutaneously (s.c., under the skin)
Study NCT02680938 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxytocin
Description: For each participant, the duration of the third stage of labor (the time period between the delivery of the fetus and the delivery of the placenta) will be recorded.~- The two groups will be compared in the following terms:~1. The duration of the third stage of labor by stopwatch.~2. Hemoglobin (Hb) difference before and 12 h after delivery.~3. The need for manual delivery of the placenta. Manual removal of the placenta will be commonly carried out under general sedation in the operating room, if the placenta will not be delivered 30 min after fetal delivery.
Study NCT02680938 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: For each participant, the duration of the third stage of labor (the time period between the delivery of the fetus and the delivery of the placenta) will be recorded.~- The two groups will be compared in the following terms:~1. The duration of the third stage of labor by stopwatch.~2. Hemoglobin (Hb) difference before and 12 h after delivery.~3. The need for manual delivery of the placenta. Manual removal of the placenta will be commonly carried out under general sedation in the operating room, if the placenta will not be delivered 30 min after fetal delivery.
Study NCT00521209 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Care Stimulating Disease Prevention Program (SCSDPP)
Description: The SCSDPP development is guided by the following premises: a) patient-directed lifestyle change or self-prescription of behavior change is potentially a more empowering, sustainable, and proactive approach to addressing personal health habits than the more conventional physician-directed approach; b) patient-directed lifestyle change or self-prescription of behavior change is potentially an important predictor of self-efficacy and long-term adherence to healthy habits; c) behavior change in isolation is less sustainable than change that is reinforced by other distinct but related changes (e.g., the potential synergy of improving diet and physical activity concurrently to prevent chronic disease); d) a multi-level change directed at the service delivery system and physician support, however small, has the added benefit of potentially reducing provider and staff burden while maximizing available clinic and community resources; and f) brief physician counseling
Study NCT00521209 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Stand procedures, no intervention
Study NCT02051751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719
Description: BYL719 will be administered orally once daily on a continuous dosing schedule and dosed on a flat-fixed dose and not adjusted by body weight or body surface area, starting on Day 2 in the dose escalation part and Day 1 in the dose expansion part. In the dose escalation part, the BYL719 starting dose will be 300mg, with anticipated dose escalation to 350mg. In the dose expansion part, BYL719 will be administered at the recommended dose determined in the dose escalation part.
Study NCT02051751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered once weekly at a dose of 80 mg/m2 i.v. (days 1, 8, 15 and 22) in a 28 day cycle in both dose escalation and expansion.
Study NCT01963793 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aprepitant
Description: Aprepitant gel (10 mg/g)
Study NCT01963793 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: gel without active component
Study NCT03813758 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: wrinkle test
Description: soaking in 40 deg water for 40 min. every 10 min the hand will be photo
Study NCT03376711 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Peer Support Program
Description: The online peer support program will entail: 1) Informational links; 2) A discussion forum (open to all participants and allowing for asynchronous contact between caregivers \& peer mentors); 3) A weekly live chat; 4) Private messaging (audio, video, and text options); and 5) Ask-a-mentor (A short video/blurb profiling each caregiving mentor will be posted including details such as gender, age, duration of care, relationship to care-recipient, and illness that care-recipient suffers from). Caregiving participants can then self-match to a peer mentor they feel is best-positioned to address their support needs.
Study NCT02544035 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Type of Toy
Description: Children will be presented with one of three (counterbalanced) toys targeted for their age group. When presented, each target toy will be paired with two additional toys from the same toy category;
Study NCT02544035 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Play Partner
Description: Each child will first play alone then play with parent.
Study NCT01059045 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: cryocontact therapy
Description: cryocontact therapy of hemangioma is realized by using liquid nitrogen cooled metal devices
Study NCT01059045 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryocontact therapy
Description: cryocontact therapy of hemangioma is realized by using liquid nitrogen cooled metal devices
Study NCT01059045 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Control
Description: No intervention
Study NCT03823586 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Questionnaire AQUA©, pediatric version
Description: A version of AQUA© recently adapted and pretested in young athletes. It is a self-administered questionnaire composed of 25 items includes items about type, duration and intensity of training sessions, allergic status, habits of children (supplements and drugs intake) and their parents (smoking), presence and burden of infections.
Study NCT00568594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL180
Study NCT00568594 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02445729 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dressing removal at 24 hours
Description: Dressing will be removed 24 hours after cesarean section and wounds will be assessed for healing and presence of infection.
Study NCT02445729 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dressing removal at 48 hours
Description: Dressing will be removed 48 hours after cesarean section and wounds will be assessed for healing and presence of infection.
Study NCT00422877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxoprexin
Description: DHA-paclitaxel
Study NCT04488081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: oral, 30 mg bid × 14 days.
Study NCT04488081 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dornase alfa
Description: For Non-intubated subjects: 2.5 mg BID until hospital discharge, improvement to room air (or baseline oxygen use prior to illness) for 24 hours, or total of 14 days of study drug, whichever comes first.~For intubated subjects: 5.0 mg BID in 10 mL normal saline until extubation or 14 days, whichever comes first. If intubated for less than 14 days, extubated subjects received 2.5 mg BID for a total Dornase treatment of 14 days, or until hospital discharge, whichever comes first.
Study NCT04488081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Oral: 400 mg BID for 7 days.
Study NCT04488081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Oral: High dose 80 mg QID for 7 days followed by 40 mg BID for a course of 14 days.
Study NCT04488081 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IC14
Description: intravenous, 4 mg/kg on day 1, followed by 2 mg/kg on days 2, 3, 4
Study NCT01284920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDV3100
Description: oral
Study NCT02831127 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: short message service group
Description: Each month after stent implantation, the investigator sent a text message by SMS to inform patients the necessity of regular stent removal/exchange and the disadvantage of delayed management, and to remind them the appropriate date to come back to the hospital for stent management. Patients were requested to respond by SMS and were encouraged to contact the investigator if they had any questions about stent management. Besides, patients received conventional reminder:After stent implantation, all patients received oral and written instructions about further management. If single or multiple plastic stents were inserted, patients were informed to come back to the hospital at 3 months for stent removal/exchange; if FCSEMS was inserted, they were informed to come back to the hospital at 6 months after ERCP.
Study NCT02831127 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional group
Description: After stent implantation, all patients received oral and written instructions about further management. If single or multiple plastic stents were inserted, patients were informed to come back to the hospital at 3 months for stent removal/exchange; if FCSEMS was inserted, they were informed to come back to the hospital at 6 months after ERCP.
Study NCT02381314 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: enoblituzumab plus ipilimumab
Description: enoblituzumab is administered by IV infusion once per week. Ipilimumab is administered by IV infusion every 3 weeks for up to 4 doses.
Study NCT03705559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaporized Marijuana
Description: Active Marijuana or Placebo, administered through vaporizer
Study NCT04488081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aviptadil
Description: Inhalation via nebulizer, 100 µg three times (TID) daily for a maximum of 14 days
Study NCT04488081 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: narsoplimab
Description: Dosed at 4 mg/kg, given as a 30-minute intravenous infusion (up to a maximum of 370 mg per infusion) twice weekly for a total of four weeks (i.e. 9 doses) or until hospital discharge whichever comes first.
Study NCT04488081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyproheptadine
Description: 4 mg tablet, with dosing regimen of 8 mg every 8 hours daily for ten (10) days. If the patient weighs less than 48 kg, the regimen is 6 mg every 8 hours daily for ten (10) days. If the participant was discharged before completion of this dosing regimen the drug was not continued.
Study NCT04488081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Modified CsA at an oral dose of 5mg/kg per day administered in two divided doses daily for 5-days.
Study NCT04138212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel, Cisplatin
Description: Paclitaxel 175mg/m2 plus Cisplatin 75mg/m2, q21d, 2 cycles
Study NCT04138212 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemoradiation therapy
Description: Paclitaxel 50mg/m2 plus Carboplatin AUC=2, q1w, 5 cycles; 41.4Gy, 1.8Gy/d\*23
Study NCT03705559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid Agonist
Description: Active Opioid Agonist or Placebo, administered intranasally
Study NCT00739310 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vest Treatment (high frequency chest wall oscillation)
Description: twice daily for 15-20 minutes
Study NCT02180685 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Anchor fixation
Study NCT04154644 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CryoPop
Description: The new CryoPop device will be tested on women with abnormal cytology. Benchmark testing occurred in the previous study and CryoPop was found to be non-inferior to standard cryotherapy device (MedGyn) in woman with normal cytology.
Study NCT01094977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: 10 mg/kg bolus with a 5 mg/kg/h infusion
Study NCT01094977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: 100 mg/kg bolus with a 10 mg/kg/h infusion
Study NCT01094977 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Study NCT01215669 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IDflu™: Split virion inactivated influenza vaccine
Description: Single dose 0.1 mL, intradermal
Study NCT00235183 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: plasma
Description: transfusion of more than 15 mL/Kg of plasma
Study NCT01215669 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaxigrip®: Split virion inactivated influenza vaccine
Description: Single dose 0.5 mL, intramuscular
Study NCT02741089 — intervention group
Intervention type: PROCEDURE
Intervention: Indication for a flexible bronchoscopy
Description: The data of patients are collected within the hospital routine documentation during the flexible bronchoscopy. The bronchoscopy is performed regardless of this study. Following the bronchoscopy the patients are asked a few questions about their health and their perception.~The follow-up of all patients is done via phone calls in order to collect data about the outcome of each patient.
Study NCT03107598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colloid preload
Description: coparaison between colloid and crystalloide loading in spinal anesthesia for cesarean section
Study NCT03107598 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: colloid preload
Description: coparaison between colloid and crystalloide loading in spinal anesthesia for cesarean section
Study NCT01616784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSII (Insulin Pump) plus DAFNE
Description: Medtronic MiniMed Paradigm Veo Insulin pumps (X54)
Study NCT01680497 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Crosslinked hyaluronic acid dermal filler
Description: All treatment details are at the discretion of the Investigator and should be guided by the Directions for Use. Up to 3 treatments will be administered: Initial treatment, optional top-up treatment at Day 14 post-initial treatment, and optional repeat treatment at Month 12 post-initial treatment.
Study NCT01193127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMS302 Solution
Study NCT01616784 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MDI (levemir® & quick acting insulin) plus DAFNE
Description: Optimised MDI therapy using rapid and twice daily (Detemir/Levemir) long-acting insulin analogues
Study NCT02658981 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-LAG-3 Monoclonal Antibody BMS 986016
Description: Given IV
Study NCT02658981 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-PD-1
Description: Given IV
Study NCT02658981 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative Studies
Study NCT02658981 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative Studies
Study NCT02658981 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD137
Description: Given IV
Study NCT01193127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMS302 Mydriatic Solution
Study NCT01180764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovaza (Omega-3 acid ethyl esters)
Description: 1g capsules, 4 capsules po daily
Study NCT01193127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMS302 Anti-inflammatory Solution
Study NCT01193127 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Balanced Salt Solution (BSS) Solution
Study NCT01180764 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching active lovaza, 1 g capsules, 4 capsules po daily
Study NCT01334983 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REST
Description: Instruction in an individualized rapid easy strength training (isotonic with therabands) and pedometer-based walking programs.
Study NCT03226548 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paycheck Plus
Description: A four-fold increase in the Earned Income Tax Credit
Study NCT01647425 — intervention group
Intervention type: BEHAVIORAL
Intervention: physician assessment
Description: * Socio-economic conditions and general features: educational level, professional status...~* Assessment of current and past use of tobacco: current smoking status reported by the patient; in lifelong non-smokers: previous history of passive smoking reported by the patient; breath carbon monoxide level; in past smokers: age of first cigarette, total reported duration of active smoking, breath carbon monoxide level...~* in current smokers: age of first tobacco use, total reported duration of active smoking; Fagerström Nicotine Dependence Test...~* Assessment of the current and past uses of alcohol: previous-year assessment using the CAGE questionnaire and the AUDIT Test; average weekly alcohol consumption over the last 12 months...~* Assessment of current use of cannabis using the Cannabis Abuse Screening Test~* Psychiatric assessment using the MINI 5.0
Study NCT00054444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan Hydrochloride Liposomes
Description: Given IV
Study NCT00796263 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: HAART
Description: 2 nuceloside/nucleotide analog reverse-transcriptase inhibitor (NRTI) class medications or Kivexa (ABC300/3TC300) orally once daily~Dolutegravir(DTG) 50 mg orally once daily
Study NCT01197755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fostamatinib
Description: fostamatinib 100 mg twice daily
Study NCT01197755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fostamatinib
Description: fostamatinib 100 mg twice daily/150 mg once daily
Study NCT00054444 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Study NCT00054444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT00116987 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Dual chamber cardiac pacemaker
Description: Physiologic pacemakers usually have two leads - one positioned in the right atrium (upper heart chamber) and one positioned in the right ventricle.
Study NCT00116987 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Single chamber cardiac pacemaker
Description: Ventricular pacemakers have a single lead (wire) positioned in the right ventricle (lower pumping chamber) to sense and pace the ventricle.
Study NCT01197755 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo twice daily
Study NCT00416884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath
Description: 30 mg on day -8 over 5-6 hours
Study NCT00416884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 30 mg/m\^2 on day -4 through day -2
Study NCT00416884 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (TBI)
Description: Total body irradiation single fraction 200 cGy at 7 cGy per minute on day 0
Study NCT00416884 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T-Cell Deplete
Description: Stem cells will be T cell depleted and given on day 0
Study NCT03654599 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baseline Surveys
Description: Baseline surveys contained a series of scaled questions, including sociodemographic variables (age, sex, cancer type, and etc), profile of mood states, social well-being, emotional processing and acceptance.
Study NCT03654599 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Baseline Surveys
Description: Baseline surveys contained a series of scaled questions, including sociodemographic variables (age, sex, cancer type, and etc), profile of mood states, social well-being, emotional processing and acceptance.
Study NCT03654599 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Stories Intervention
Description: Digital Stories Intervention Videos contain the following content: caregiver burden, positive and cognitive coping, support from other family and friends, fear of losing the patient, spirituality, guilt of being sick, and expressing emotions/feelings
Study NCT03654599 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information Control Intervention
Description: Information Control Intervention Videos include Information about post-HCT. The topics in the IC include specific guidelines to return to wellness post HCT through (1) an exercise plan, (2) a nutrition (dietary) plan, (3) pain management, (4) information about the complications, (5) caregiver responsibilities, (6) social support, (7) preventing from infections, and (8) symptom management. Participants randomized to the IC will receive the full set of DS modules only after the final 3-month post-intervention data collection point has passed and they can view them as desired.